GPCR logo

GPCRStructure Therapeutics Inc - ADR

$41.00
$0.19
(0.51%)
Today
Closed $37.77
$3.23
(8.55%)
After Hours
Updated: 07:30 PM EDT
EarningsAug 6
Mkt Cap$2.67B
Vol764,424.00
News
all
press releases
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
Zacks
News Placeholder
More News
News Placeholder
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Zacks
News Placeholder
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.
Zacks
News Placeholder
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
Zacks
News Placeholder
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Stocktwits
News Placeholder
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Zacks
News Placeholder
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Key PointsDeep Track Capital acquired 168,066 shares of Structure Therapeutics last quarter; the estimated trade size was $11.50 million (based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Zacks
News Placeholder
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Zacks
News Placeholder
Monashee Scales Back Its Bet on Structure Therapeutics
Key PointsMonashee sold 175,000 Structure Therapeutics shares; estimated trade size approximately $11.98 million based on the mean unadjusted close for the quarter...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.